Literature DB >> 19474105

Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1.

Catherine A Blish1, Zahra Jalalian-Lechak, Stephanie Rainwater, Minh-An Nguyen, Ozge C Dogan, Julie Overbaugh.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) variants that are transmitted to newly infected individuals are the primary targets of interventions, such as vaccines and microbicides, aimed at preventing new infections. Newly acquired subtype A, B, and C variants have been the focus of neutralization studies, although many of these viruses, particularly of subtypes A and B, represent viruses circulating more than a decade ago. In order to better represent the global diversity of transmitted HIV-1 variants, an additional 31 sexually transmitted Kenyan HIV-1 env genes, representing several recent infections with subtype A, as well as subtypes A/D, C, and D, were cloned, and their neutralization profiles were characterized. Most env variants were resistant to neutralization by the monoclonal antibodies (MAbs) b12, 4E10, 2F5, and 2G12, suggesting that targeting the epitopes of these MAbs may not be effective against variants that are spreading in areas of endemicity. However, significant cross-subtype neutralization by plasma was observed, indicating that there may be other epitopes, not yet defined by the limited available MAbs, which could be recognized more broadly.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474105      PMCID: PMC2708608          DOI: 10.1128/JVI.00673-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals.

Authors:  Becky Schweighardt; Yang Liu; Wei Huang; Colombe Chappey; Yolanda S Lie; Christos J Petropoulos; Terri Wrin
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

3.  Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Authors:  Madhumita Mahalanabis; Pushpa Jayaraman; Toshiyuki Miura; Florencia Pereyra; E Michael Chester; Barbra Richardson; Bruce Walker; Nancy L Haigwood
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

4.  Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Authors:  E S Gray; P L Moore; I A Choge; J M Decker; F Bibollet-Ruche; H Li; N Leseka; F Treurnicht; K Mlisana; G M Shaw; S S Abdool Karim; C Williamson; L Morris
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro.

Authors:  Esther D Quakkelaar; Evelien M Bunnik; Floris P J van Alphen; Brigitte D M Boeser-Nunnink; Ad C van Nuenen; Hanneke Schuitemaker
Journal:  Virology       Date:  2007-03-13       Impact factor: 3.616

6.  Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Authors:  Catherine A Blish; Ozge C Dogan; Nina R Derby; Minh-An Nguyen; Bhavna Chohan; Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 7.  Transmission of HIV-1 in the face of neutralizing antibodies.

Authors:  Catherine A Blish; Wendy M Blay; Nancy L Haigwood; Julie Overbaugh
Journal:  Curr HIV Res       Date:  2007-11       Impact factor: 1.581

8.  Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B.

Authors:  Elin Solomonovna Gray; Tammy Meyers; Glenda Gray; David Charles Montefiori; Lynn Morris
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

9.  Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.

Authors:  Catherine A Blish; Minh-An Nguyen; Julie Overbaugh
Journal:  PLoS Med       Date:  2008-01-03       Impact factor: 11.069

10.  Chronic HIV-1 infection frequently fails to protect against superinfection.

Authors:  Anne Piantadosi; Bhavna Chohan; Vrasha Chohan; R Scott McClelland; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  41 in total

Review 1.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

2.  Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.

Authors:  Rajesh Abraham Jacob; Fatima Abrahams; Marcel Tongo; Michael Schomaker; Paul Roux; Eitel Mpoudi Ngole; Wendy A Burgers; Jeffrey R Dorfman
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

3.  The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant.

Authors:  Nicholas M Provine; Valerie Cortez; Vrasha Chohan; Julie Overbaugh
Journal:  Virology       Date:  2012-02-25       Impact factor: 3.616

4.  Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity.

Authors:  Francesca Curreli; Dmitry S Belov; Ranjith R Ramesh; Naisargi Patel; Andrea Altieri; Alexander V Kurkin; Asim K Debnath
Journal:  Bioorg Med Chem       Date:  2016-09-24       Impact factor: 3.641

5.  Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Dmitry S Belov; Pavel O Markov; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

6.  A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection.

Authors:  Daryl Humes; Sandra Emery; Elizabeth Laws; Julie Overbaugh
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

7.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

8.  Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Authors:  Catherine A Blish; D Noah Sather; George Sellhorn; Leonidas Stamatatos; Yide Sun; Indresh Srivastava; Susan W Barnett; Brad Cleveland; Julie Overbaugh; Shiu-lok Hu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  Chronic HIV-1 Infection Impairs Superantigen-Induced Activation of Peripheral CD4+CXCR5+PD-1+ Cells, With Relative Preservation of Recall Antigen-Specific Responses.

Authors:  Katherine J Nicholas; David K Flaherty; Rita M Smith; D Noah Sather; Spyros A Kalams
Journal:  J Acquir Immune Defic Syndr       Date:  2017-01-01       Impact factor: 3.731

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.